Printer Friendly
The Free Library
14,794,102 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Eisai Subsidiary Launches Research Operations in Kobe.


Tokyo, Japan, Oct 4, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - KAN Research Institute, Eisai's research subsidiary, has begun research operations in its new facilities in the Kobe Medical Industry Development Project site.

KAN aims to discover innovative ideas and technology that lead to new pharmaceutical development, focusing on cellomics in order to explore how cells interact with each other and orchestrate to shape vital activities of a human body.

KAN will mainly target neurology areas such as Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia.  and Parkinson's disease, oncology areas such as malignant tumor, metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases  
1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to
 and vascularization vascularization /vas·cu·lar·iza·tion/ (vas?ku-ler-i-za´shun)
1. the process of becoming vascular.

2. angiogenesis.

3. the surgically induced development of vessels in a tissue.
, and immunology and inflammation areas including rheumatoid arthritis and inflammatory bowel disease inflammatory bowel disease
n. Abbr. IBD
Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine.
.

The research is expected to produce outcome for use in translational research from basic study for drug discovery, which will likely contribute to the R&D activities of Eisai worldwide.

The reinforced facilities will allow KAN to take advantage of the bio cluster district on the site to accelerate research through the extended network of researchers who work there.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Oct 4, 2006
Words:168
Previous Article:Kyowa Hakko Licenses Anticancer Agent KW-2401 to Keryx Biopharmaceuticals.
Next Article:Bitway Starts Mobile Video Distribution Service for FOMA Handsets.



Related Articles
Research giant to build 200,000 s/f HQ facility.(NEW JERSEY)
Eisai Resubmits Supplemental New Drug Application for Aricept, Alzheimers Disease Drug, to FDA.
Eisai Establishes European Strategic Business Hub in the U.K.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
New R&D facility for pharmaceutics giant.
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.
Eisai Establishes New Manufacturing Subsidiary in United Kingdom.

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles